Back to Home
    Research & Industry

    ASCO Annual Meeting 2027: What to Expect From Oncology's Biggest Stage

    By RegenMed Review Editorial Team · Medically Reviewed by the RegenMed Review Editorial Team
    November 11, 20264 min read
    ASCO Annual Meeting 2027: What to Expect From Oncology's Biggest Stage

    What this article covers

    What This Article Covers
    The American Society of Clinical Oncology (ASCO) will hold its 2027 Annual Meeting at McCormick Place Convention Center in Chicago, Illinois, running June 4 through June 8, 2027. This preview looks at what the meeting is, why it matters to anyone following cancer immunotherapy and cell-based cancer treatment, and what kinds of research tend to surface there based on recent years' programming.
    What the ASCO Annual Meeting Is
    S. professional organization for clinical oncologists, and its Annual Meeting is widely regarded as one of the largest and most influential gatherings in cancer medicine.
    Why This Meeting Matters for Immunotherapy and Cell Therapy
    Although ASCO is a general oncology meeting rather than an immunotherapy-specific congress, recent editions have featured a substantial amount of programming on checkpoint inhibitors, CAR T-cell therapy, bispecific antibodies, antibody-drug conjugates (ADCs), and therapeutic cancer vaccines. At the 2026 meeting, for example, leadership from the Parker Institute for Cancer Immunotherapy highlighted cell-based therapies, in vivo cell engineering, and combination immunotherapy strategies as major talking points, alongside continued momentum for ADCs and precision biomarker tools.
    What's Likely on the Agenda
    Based on the structure of recent ASCO Annual Meetings, attendees can generally expect:
    Who Attends and Why It Matters
    The meeting draws practicing oncologists, academic researchers, pharmaceutical and biotech companies, patient advocacy groups, and health journalists. For patients and caregivers researching emerging cancer therapies, ASCO coverage is often one of the fastest ways that new trial data — including data on cell and immune-based therapies — reaches public reporting, well before formal journal publication in some cases.

    What This Article Covers

    The American Society of Clinical Oncology (ASCO) will hold its 2027 Annual Meeting at McCormick Place Convention Center in Chicago, Illinois, running June 4 through June 8, 2027. This preview looks at what the meeting is, why it matters to anyone following cancer immunotherapy and cell-based cancer treatment, and what kinds of research tend to surface there based on recent years' programming.

    What the ASCO Annual Meeting Is

    ASCO is the leading U.S. professional organization for clinical oncologists, and its Annual Meeting is widely regarded as one of the largest and most influential gatherings in cancer medicine. Tens of thousands of oncologists, researchers, patient advocates, industry representatives, and journalists from around the world typically attend. The meeting is also where many practice-changing clinical trial results are presented for the first time, making it a closely watched event for anyone tracking the pace of progress in oncology.

    Why This Meeting Matters for Immunotherapy and Cell Therapy

    Although ASCO is a general oncology meeting rather than an immunotherapy-specific congress, recent editions have featured a substantial amount of programming on checkpoint inhibitors, CAR T-cell therapy, bispecific antibodies, antibody-drug conjugates (ADCs), and therapeutic cancer vaccines. At the 2026 meeting, for example, leadership from the Parker Institute for Cancer Immunotherapy highlighted cell-based therapies, in vivo cell engineering, and combination immunotherapy strategies as major talking points, alongside continued momentum for ADCs and precision biomarker tools. Given this trajectory, the 2027 meeting is reasonably expected to carry forward significant immuno-oncology content, though ASCO has not yet published its 2027 abstract titles or program theme.

    What's Likely on the Agenda

    Based on the structure of recent ASCO Annual Meetings, attendees can generally expect:

    • Plenary and late-breaking abstract sessions featuring major randomized trial results
    • Disease-specific tracks spanning solid tumors and hematologic malignancies
    • Dedicated sessions on cellular therapies, immunotherapy combinations, and biomarker-driven patient selection
    • Educational sessions aimed at translating research into clinical practice
    • A large exhibit hall and industry-sponsored symposia

    The specific scientific program and keynote themes for 2027 had not yet been published as of this writing, and readers should check ASCO's official site closer to the meeting for confirmed session listings.

    Who Attends and Why It Matters

    The meeting draws practicing oncologists, academic researchers, pharmaceutical and biotech companies, patient advocacy groups, and health journalists. For patients and caregivers researching emerging cancer therapies, ASCO coverage is often one of the fastest ways that new trial data — including data on cell and immune-based therapies — reaches public reporting, well before formal journal publication in some cases.

    How to Follow the Research Afterward

    ASCO typically makes abstracts available through its meeting library and publishes select presentations in its affiliated journals. Medical and trade press, including outlets covering oncology and biotech, generally publish summaries of key presentations within days of each session.

    Bottom Line

    The 2027 ASCO Annual Meeting is confirmed to take place June 4–8, 2027, at McCormick Place in Chicago, continuing ASCO's role as one of oncology's largest and most closely watched scientific gatherings. While the full 2027 scientific program has not yet been released, recent years' emphasis on cell therapy, immunotherapy combinations, and antibody-drug conjugates suggests this area will again be well represented. As with any major conference, readers should treat meeting presentations as research findings — often early-stage or interim — rather than as approved treatments, and should look for peer-reviewed publication and regulatory review before drawing firm conclusions about any specific therapy discussed there.

    Key Questions Answered

    When and where is the ASCO 2027 Annual Meeting?
    It is scheduled for June 4–8, 2027, at McCormick Place Convention Center in Chicago, Illinois.
    Has the 2027 scientific program been released?
    Not as of this writing. ASCO had not yet published 2027 abstract titles or a program theme, so readers should check ASCO's official site closer to the meeting.
    How should readers interpret results presented at ASCO?
    As research findings that are often early-stage or interim, not approved treatments. Look for peer-reviewed publication and regulatory review before drawing firm conclusions.

    Sources

    • 2027 American Society of Clinical Oncology (ASCO) Annual Meeting, UroToday, 2026, https://www.urotoday.com/calendar-events/2027-american-society-of-clinical-oncology-asco-annual-meeting.html
    • ASCO Annual Meeting 2027, ShowsBee Industry News, 2026, https://www.showsbee.com/fairs/97297-ASCO-Annual-Meeting-2027.html
    • ASCO 2027 Industry Expert Theater Program, J. Spargo & Associates (official ASCO exhibits/events contractor), 2026, https://events.jspargo.com/ASCO27/CUSTOM/PDF27/ASCO2027IET.pdf
    • ASCO Kickoff: Cancer Vaccines, Cell Therapies, and AI-Driven Precision Oncology Signal the Next Era of Immunotherapy, Pharmacy Times, 2026, https://www.pharmacytimes.com/view/asco-kickoff-cancer-vaccines-cell-therapies-and-ai-driven-precision-oncology-signal-the-next-era-of-immunotherapy
    • ASCO Annual Meeting resource overview, Sermo, 2026, https://www.sermo.com/resources/asco-annual-meeting

    Related Articles

    The Review Dispatch

    Our weekly briefing on the regenerative medicine landscape, for researchers, clinicians, and investors.

    regenmedreview

    regenmedreview is an independent reference library covering stem cell therapy and cancer immunotherapy research — compiled for researchers, clinicians, and patients exploring the field.

    The information on this site is for general educational purposes only and does not constitute medical advice. Regenerative medicine treatments discussed here may not be approved or available in all jurisdictions. Always consult a licensed physician before making treatment decisions.

    © 2026 regenmedreview. All rights reserved.Independent. Unaffiliated. Reader-supported.